Literature DB >> 6631711

Pharmacokinetics of chlorzoxazone in humans.

R K Desiraju, N L Renzi, R K Nayak, K T Ng.   

Abstract

Twenty-three normal male subjects received 900 mg of acetaminophen and 750 mg of chlorzoxazone as an oral suspension. Analysis of plasma samples indicated a rapid absorption and rapid elimination of chlorzoxazone. Average values of the elimination half-life and plasma clearance were 1.12 +/- 0.48 hr and 148.0 +/- 39.9 ml/min, respectively. Analysis of urine samples showed that chlorzoxazone was eliminated from the body as the glucuronide conjugate of the intermediate metabolite 6-hydroxychlorzoxazone, to the extent of 74% of the dose. The plasma and the urinary excretion data were fitted to theoretical equations, and excellent fits were obtained using a five-parameter pharmacokinetic model.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6631711     DOI: 10.1002/jps.2600720905

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses.

Authors:  Nicolas Hohmann; Antje Blank; Jürgen Burhenne; Yosuke Suzuki; Gerd Mikus; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2019-08-09       Impact factor: 4.335

2.  Chlorzoxazone as a cause of acute liver failure requiring liver transplantation.

Authors:  James Jackson; Frank A Anania
Journal:  Dig Dis Sci       Date:  2007-03-28       Impact factor: 3.199

3.  Similar effect of quercetin on CYP2E1 and CYP2C9 activities in humans?

Authors:  Shingen Misaka; Kenju Shimomura
Journal:  Eur J Clin Pharmacol       Date:  2018-05-17       Impact factor: 2.953

4.  Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans.

Authors:  Zaiqi Wang; Stephen D Hall; Juan F Maya; Lang Li; Ali Asghar; J C Gorski
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

5.  Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity.

Authors:  Lena Ernstgård; Margareta Warholm; Gunnar Johanson
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

6.  Pharmacodynamics of zoxazolamine and chlorzoxazone in rats.

Authors:  M Yasuhara; G Levy
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

7.  The effect of quercetin on the pharmacokinetics of chlorzoxazone, a CYP2E1 substrate, in healthy subjects.

Authors:  Satish Kumar Bedada; Prasad Neerati
Journal:  Eur J Clin Pharmacol       Date:  2017-10-05       Impact factor: 2.953

8.  Effects of Oral Rutaecarpine on the Pharmacokinetics of Intravenous Chlorzoxazone in Rats.

Authors:  Sudeep R Bista; Sang Kyu Lee; Dinesh Thapa; Mi Jeong Kang; Young Min Seo; Ju Hyun Kim; Dong Hyeon Kim; Yurngdong Jahng; Jung Ae Kim; Tae Cheon Jeong
Journal:  Toxicol Res       Date:  2008-09-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.